Japan's 'Miracle Cure' Clinics Under Fire After Deaths

Regenerative medicine treatments in Japan, particularly those offered at private clinics, are under intense scrutiny due to patient fatalities and regulatory breaches. Claims of "reversing aging" and "attacking cancer cells" are being used to promote therapies like stem cell treatments and, more recently, exosome-based procedures. These exosome treatments, which utilize tiny cell-released structures, currently operate outside existing legislation, prompting the health ministry to consider enhancing regulations.

The current law categorizes regenerative medicine by risk, from high-risk embryonic stem cell therapies to lower-risk treatments using a patient's own somatic cells. Medical institutions must submit treatment plans for review. However, reports indicate that the review process may be insufficient, with some committees suspected of conflicts of interest. This has led to concerns that safety and scientific validity are not being adequately discussed, turning the review into a potential formality.

Serious adverse events have highlighted these safety issues. In 2024, two patients were hospitalized with sepsis after receiving immune cell treatments for cancer prevention, suspected to be due to bacterial contamination during culturing. Further deaths occurred in 2025 and 2026 following treatments involving fat-derived stem cells. The ministry has issued emergency orders, but some clinics have attempted to evade action by closing and reappearing elsewhere.

A working group is examining how to better assess the validity of regenerative medicine offered outside research, improve patient information, and enhance adverse event reporting. The group aims to publish a report by the end of the current fiscal year, which concludes in March. Meanwhile, the rise of exosome treatments, which also carry risks of contamination, necessitates their inclusion under the regenerative medicine safety law, according to some experts.